KOREA (SOUTH); SWITZERLAND —Samsung Biologics has initiated a rights offering valued at approximately KRW 3 trillion to secure funding for its dual-pronged expansion strategy. The South Korean contract development and manufacturing organization (CDMO) will allocate roughly KRW 2.71 billion toward the previously announced acquisition of Switzerland-based PolyPeptide Group, with the remaining KRW 290 billion directed toward scaling operations at its Songdo Bio Campus II facility.
The capital injection represents a critical financial maneuver enabling Samsung Biologics to transition beyond its traditional antibody-focused portfolio. By integrating PolyPeptide’s peptide manufacturing capabilities, the company aims to capture growing demand for diverse therapeutic modalities including peptide-based drugs and antibody-drug conjugates. This strategic pivot addresses evolving pharmaceutical industry requirements for specialized manufacturing partners capable of handling complex molecular structures.
Simultaneously, the Bio Campus II expansion continues the sequential activation of Plants 6 through 8, following the 2025 completion of Plant 5. This infrastructure development will elevate Samsung Biologics’ total global manufacturing capacity to 1.385 million liters by 2032, reinforcing its position among the world’s largest biologics manufacturers. The capacity increase responds to sustained industry-wide demand for outsourced production facilities amid robust pharmaceutical pipeline growth.
The rights offering structure includes approximately 2.27 million new common shares priced at KRW 1,322,000 per share, representing a fifteen percent discount from the reference price. Under Korea’s Capital Markets Act, twenty percent of the newly issued shares are allocated to the employee stock ownership association, while existing shareholders receive proportional subscription rights. Unsubscribed shares will be offered through a public placement mechanism, with any residual inventory absorbed by the lead underwriter.
This financing event carries significant implications for the global CDMO sector. The acquisition of PolyPeptide establishes Samsung Biologics as a multi-modality manufacturer with enhanced geographic presence across Europe, the United States, and India. Competitors in the contract manufacturing space must now contend with an integrated player combining large-scale biologics production with specialized peptide synthesis capabilities. Pharmaceutical companies seeking outsourcing partners will benefit from expanded service offerings spanning multiple therapeutic categories.
For investors and stakeholders, the rights offering dilutes existing equity positions while providing capital for value-accretive growth initiatives. The fifteen percent discount on new shares creates immediate pricing pressure but aligns with standard market practices for rights offerings of this magnitude. Shareholders unwilling to participate may trade subscription rights certificates during the designated period, maintaining liquidity options throughout the process.
The transaction timeline progresses with securities registration effectiveness scheduled for September 30, followed by share allocation on October 6. Existing shareholder subscriptions occur November 9-10, with public offering phases November 12-13. New shares are targeted for listing on November 30, completing the capital formation process within the current fiscal year.
Samsung Biologics operates as a leading global CDMO headquartered in Incheon, South Korea, providing end-to-end development and manufacturing services for biopharmaceutical companies. The company maintains extensive production facilities across multiple continents and serves clients ranging from emerging biotechnology firms to established multinational pharmaceutical corporations. Its integrated service model encompasses cell line development, process optimization, clinical and commercial manufacturing, and analytical testing across antibody, vaccine, and advanced therapy modalities.
